ArticlemBio2019
Efficient Inhibition of Human Papillomavirus Infection by L2 Minor Capsid-Derived Lipopeptide.
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Atomic resolution structure of human papillomavirus bound to heparin.Nature communications · 2026Article
- Article
- Effect of HPV Oncoprotein on Carbohydrate and Lipid Metabolism in Tumor Cells.Current cancer drug targets · 2024Review
- Glucosylceramide is essential for Heartland and Dabie bandavirus glycoprotein-induced membrane fusion.PLoS pathogens · 2023Article
- The Activity ofInternational journal of molecular sciences · 2022Article
- Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum.Microbiology spectrum · 2022Article
- Human Papillomavirus Type 16 L2 Gene Sequence Variation Analysis in Indonesian Cervical Cancer Specimens.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Article
- Human Papillomavirus (HPV) Entry Inhibitors.Advances in experimental medicine and biology · 2022Article
- Advances in Targeting HPV Infection as Potential Alternative Prophylactic Means.International journal of molecular sciences · 2021Review
- Papillomaviruses Go Retro.Pathogens (Basel, Switzerland) · 2020Review
- Cell-penetrating peptide inhibits retromer-mediated human papillomavirus trafficking during virus entry.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7/C/EBPβ Signaling Pathway in Cervical Cancer Cell Lines.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
The amino (N)-terminal region of human papillomavirus (HPV) minor capsid protein (L2) is a highly conserved region which is essential for establishing viral infection. Despite its importance in viral infectivity, the role of the HPV N-terminal domain has yet to be fully characterized. Using fine mapping analysis, we identified a 36-amino-acid (aa) peptide sequence of the L2 N terminus, termed L2N, that is critical for HPV infection. Ectopic expression of L2N with the transmembrane sequence on the target cell surface conferred resistance to HPV infection. Additionally, L2N peptide with chemical or enzymatic lipidation at the carboxyl (C) terminus efficiently abrogated HPV infection in target cells. Among the synthetic L2N lipopeptides, a stearoylated lipopeptide spanning aa 13 to 46 (13-46st) exhibited the most potent anti-HPV activity, with a half-maximal inhibitory concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.